Gan & Lee Pharmaceuticals (603087) Fundamentals 2026 — P/E 39.1x, Revenue Analysis | SniperIQ
Gan & Lee Pharmaceuticals (603087) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥40.4B, trading at ¥67.69 on the SHH. This SniperIQ fundamentals page covers Gan & Lee Pharmaceuticals's valuation (P/E 39.1x, P/B 3.4x), profitability (net margin 26.0%), revenue (¥4.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gan & Lee Pharmaceuticals's market cap?
Gan & Lee Pharmaceuticals (603087) has a market capitalization of approximately ¥40.4B, trading at ¥67.69 on the SHH. Market cap moves with the live share price.
What is Gan & Lee Pharmaceuticals's P/E ratio?
Gan & Lee Pharmaceuticals's trailing twelve-month P/E ratio is 39.1x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gan & Lee Pharmaceuticals?
Gan & Lee Pharmaceuticals runs a net profit margin of 26.0%, a gross margin of 74.4%, and an operating margin of 18.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gan & Lee Pharmaceuticals generate?
Gan & Lee Pharmaceuticals reported revenue of ¥4.0B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 1.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Gan & Lee Pharmaceuticals pay a dividend?
Gan & Lee Pharmaceuticals offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Gan & Lee Pharmaceuticals financially healthy?
Gan & Lee Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 7.99x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gan & Lee Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gan & Lee Pharmaceuticals (603087) the key facts are: market cap ¥40.4B, P/E 39.1x, revenue ¥4.0B, 52-week range 51.51-82.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Gan & Lee Pharmaceuticals's full fundamentals live
Get Gan & Lee Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.